RESUMO
BACKGROUND: Several non-invasive skin imaging methods have been developed in recent years. Line-field confocal optical coherence tomography (LC-OCT) is one of them, leading to the best compromise in terms of resolution and penetration depth. Skin biopsies are an essential technique in paediatric dermatology, but they are a major stressful event for the child and their parents. Current LC-OCT studies have not been dedicated to a paediatric population. If, however, LC-OCT proves to be helpful in children, it may help guide and decrease a certain number of skin biopsies. OBJECTIVES: (1) To evaluate the feasibility of using LC-OCT in paediatric patients, and (2) to assess the maturation of skin structures in children over time with this method. METHODS: In vivo LC-OCT images were collected on six specific body regions (forehead, forearm, chest, back, dorsum of the hand and palmar surface) and in six age groups (between the ages of 0 and 16 years). RESULTS: In all body areas and age groups assessed, 9 of 10 images were rated as good-to-excellent, the only exception were the images acquired on the palmar surface. LC-OCT allowed visualizing very well the skin structures up to a penetration of 500 µm. We observed that the body regions located on the upper extremities of the body (forearm, dorsum of the hand and palmar surface) showed both a maturation on their structure and differences in thickness with respect to the other regions evaluated. CONCLUSIONS: LC-OCT can easily be used for non-invasive imaging of children's skin and allows to document progressive skin changes in the different age groups. It may be a useful asset for imaging and diagnosing superficial skin disorders and as such reducing the number of invasive procedures while increasing the speed of diagnosis in the paediatric population.
Assuntos
Dermatologia , Dermatopatias , Criança , Humanos , Recém-Nascido , Lactente , Pré-Escolar , Adolescente , Tomografia de Coerência Óptica/métodos , Pele/diagnóstico por imagem , Pele/patologia , Dermatopatias/diagnóstico , Dermatologia/métodos , AntebraçoRESUMO
BACKGROUND: Postzygotic mutations in FGFR2 have been identified in mosaic forms of acne, keratinocytic epidermal nevi, nevoid acanthosis nigricans / rounded and velvety epidermal nevus and in two fetuses with papillomatous pedunculated sebaceous nevus (PPSN). OBJECTIVES: To determine the clinical and genetic characteristics of children with cerebriform, papillomatous and pedunculated variants of sebaceous nevi. METHODS: Infants diagnosed with sebaceous nevi characterized by a cerebriform, papillomatous and/or pedunculated morphology over a 10-year period (2010-2019) at three paediatric dermatology centres in Switzerland and France were included in this case series. Clinical and histological characteristics were assessed. Next-generation sequencing was used to assess for FGFR2 mutations. RESULTS: All nevi were located on the head, with a rounded or linear shape and a typical cerebriform, sometimes papillomatous and pedunculated, surface. No associated extracutaneous anomalies were found. Nevi harboured postzygotic mutations in the transmembrane domain of FGFR2 in 6/8 children (75%), either the known specific p.(Cys382Arg) mutation in 5 cases, or a novel mutation, p.(Val395Asp), in one. CONCLUSIONS: We found an exquisite genotype-phenotype correlation in these rare nevi, with specific postzygotic mutations in the transmembrane domain of FGFR2. As not all lesions were truly papillomatous and pedunculated, the term cerebriform sebaceous nevus (CSN) appears more suitable than PPSN to describe this entity. The cerebriform pattern of CSN is reminiscent of cutis gyrata, as seen in Beare-Stevenson syndrome, which is caused by closely related germline FGFR2 mutations. While clinically impressive, CSN seem to carry a good prognosis and a low risk for extracutaneous associations.
Assuntos
Nevo , Receptor Tipo 2 de Fator de Crescimento de Fibroblastos , Neoplasias Cutâneas , Humanos , Mutação , Nevo/genética , Organoides , Receptor Tipo 2 de Fator de Crescimento de Fibroblastos/genética , Neoplasias Cutâneas/genéticaAssuntos
Anafilaxia , COVID-19 , Dermatite Atópica , Vacinas , Vacinas contra COVID-19 , Dermatite Atópica/prevenção & controle , Humanos , SARS-CoV-2Assuntos
Produtos Biológicos , COVID-19 , Dermatite Atópica , Adulto , Dermatite Atópica/tratamento farmacológico , Humanos , SARS-CoV-2 , VacinaçãoRESUMO
We report an outbreak of Trichophyton soudanense causing tinea capitis and corporis in an orphanage in Myanmar. The thirty orphan children were suspected to have anthropophilic tinea but zoonotic tinea could not be excluded as all children were playing with stray dogs. Direct mycological examinations of hair and scalp samples showed filaments but culture assays remained sterile. We revealed T. soudanense as the infectious agent by PCR amplification of extracted fungal DNA and further sequencing of the PCR products. Children were successfully treated by terbinafine and reinfection was prevented by hygiene measures. This case report shed the light on T. soudanense infection on another continent than Africa and on the significant help of PCR identification.
Assuntos
Arthrodermataceae/isolamento & purificação , Surtos de Doenças , Orfanatos , Tinha do Couro Cabeludo/diagnóstico , Tinha/diagnóstico , Alopecia/diagnóstico , Alopecia/epidemiologia , Alopecia/microbiologia , Animais , Criança , Crianças Órfãs , Doenças do Cão/microbiologia , Doenças do Cão/transmissão , Cães , Feminino , Humanos , Masculino , Mianmar/epidemiologia , Couro Cabeludo/microbiologia , Tinha/epidemiologia , Tinha/microbiologia , Tinha do Couro Cabeludo/epidemiologia , Tinha do Couro Cabeludo/microbiologia , Zoonoses/microbiologiaAssuntos
Infecções por Coronavirus/epidemiologia , Dermatite Atópica/epidemiologia , Imunossupressores/uso terapêutico , Pneumonia Viral/epidemiologia , Guias de Prática Clínica como Assunto , Síndrome Respiratória Aguda Grave/epidemiologia , Comitês Consultivos , COVID-19 , Comorbidade , Infecções por Coronavirus/imunologia , Dermatite Atópica/tratamento farmacológico , Dermatite Atópica/imunologia , Europa (Continente) , Feminino , Humanos , Hospedeiro Imunocomprometido/efeitos dos fármacos , Masculino , Pandemias , Pneumonia Viral/imunologia , Medição de Risco , Síndrome Respiratória Aguda Grave/imunologia , Resultado do TratamentoRESUMO
Atopic dermatitis (AD) is a common inflammatory skin disease that affects both children and adults, including a large number of adults of reproductive age. Several guidelines for the treatment of AD exist, yet specific recommendations for the treatment of pregnant or lactating women and for adults planning to have a child are often lacking. This position paper from the European Task force on Atopic Dermatitis (ETFAD) is based on up-to-date scientific literature on treating pregnant and lactating women as wells as adults with AD planning to have a child. It is based on the expert opinions of members of the ETFAD and on existing safety data on the proposed treatments, many of which are derived from patients with other inflammatory diseases or from transplantation medicine. For treating future parents, as well as pregnant and lactating women with AD, the use of topical treatments including moisturizers, topical corticosteroids, tacrolimus, antiseptics such as chlorhexidine, octenidine, potassium permanganate and sodium hypochlorite (bleach) is deemed to be safe. Ultraviolet (UV) therapy may also be used. Systemic treatment should be prescribed only after careful consideration. According to the opinion of the ETFAD, treatment should be restricted to systemic corticosteroids and cyclosporine A, and, in selected cases, azathioprine.
Assuntos
Dermatite Atópica/terapia , Fármacos Dermatológicos/uso terapêutico , Lactação , Cuidado Pré-Concepcional , Terapia Ultravioleta , Adulto , Comitês Consultivos , Europa (Continente) , Feminino , Humanos , Masculino , GravidezRESUMO
This guideline was developed as a joint interdisciplinary European project, including physicians from all relevant disciplines as well as patients. It is a consensus-based guideline, taking available evidence from other guidelines, systematic reviews and published studies into account. This second part of the guideline covers antimicrobial therapy, systemic treatment, allergen-specific immunotherapy, complementary medicine, psychosomatic counselling and educational interventions, whereas the first part covers methods, patient perspective, general measures and avoidance strategies, basic emollient treatment and bathing, dietary intervention, topical anti-inflammatory therapy, phototherapy and antipruritic therapy. Management of AE must consider the individual clinical variability of the disease. Systemic immunosuppressive treatment with cyclosporine, methotrexate, azathioprine and mycophenolic acid is established option for severe refractory cases, and widely available. Biologicals targeting the T helper 2 pathway such as dupilumab may be a safe and effective, disease-modifying alternative when available. Oral drugs such as JAK inhibitors and histamine 4 receptor antagonists are in development. Microbial colonization and superinfection may cause disease exacerbation and can require additional antimicrobial treatment. Allergen-specific immunotherapy with aeroallergens may be considered in selected cases. Psychosomatic counselling is recommended especially in stress-induced exacerbations. Therapeutic patient education ('Eczema school') is recommended for children and adult patients. General measures, basic emollient treatment, bathing, dietary intervention, topical anti-inflammatory therapy, phototherapy and antipruritic therapy have been addressed in the first part of the guideline.
Assuntos
Consenso , Dermatite Atópica/terapia , Eczema/terapia , Guias de Prática Clínica como Assunto , Adulto , Alérgenos/toxicidade , Anti-Infecciosos/uso terapêutico , Anti-Inflamatórios/uso terapêutico , Criança , Dermatite Atópica/dietoterapia , Dermatite Atópica/tratamento farmacológico , Dermatite Atópica/microbiologia , Fármacos Dermatológicos/uso terapêutico , Eczema/dietoterapia , Eczema/tratamento farmacológico , Eczema/microbiologia , Europa (Continente) , Humanos , Imunossupressores/uso terapêutico , Imunoterapia , Educação de Pacientes como AssuntoRESUMO
This guideline was developed as a joint interdisciplinary European project, including physicians from all relevant disciplines as well as patients. It is a consensus-based guideline, taking available evidence from other guidelines, systematic reviews and published studies into account. This first part of the guideline covers methods, patient perspective, general measures and avoidance strategies, basic emollient treatment and bathing, dietary intervention, topical anti-inflammatory therapy, phototherapy and antipruritic therapy, whereas the second part covers antimicrobial therapy, systemic treatment, allergen-specific immunotherapy, complementary medicine, psychosomatic counselling and educational interventions. Management of AE must consider the individual clinical variability of the disease; highly standardized treatment rules are not recommended. Basic therapy is focused on treatment of disturbed barrier function by hydrating and lubricating topical treatment, besides further avoidance of specific and unspecific provocation factors. Topical anti-inflammatory treatment based on glucocorticosteroids and calcineurin inhibitors is used for flare management and for proactive therapy for long-term control. Topical corticosteroids remain the mainstay of therapy, whereas tacrolimus and pimecrolimus are preferred in sensitive skin areas and for long-term use. Topical phosphodiesterase inhibitors may be a treatment alternative when available. Adjuvant therapy includes UV irradiation, preferably with UVB 311 nm or UVA1. Pruritus is targeted with the majority of the recommended therapies, but some patients may need additional antipruritic therapy. Antimicrobial therapy, systemic anti-inflammatory treatment, immunotherapy, complementary medicine and educational intervention will be addressed in part II of the guideline.
Assuntos
Dermatite Atópica/etiologia , Dermatite Atópica/terapia , Emolientes/uso terapêutico , Glucocorticoides/uso terapêutico , Prurido/terapia , Higiene da Pele , Administração Cutânea , Adolescente , Adulto , Alérgenos/efeitos adversos , Inibidores de Calcineurina/uso terapêutico , Criança , Pré-Escolar , Consenso , Dieta , Exposição Ambiental/prevenção & controle , Poluentes Ambientais/efeitos adversos , Europa (Continente) , Hipersensibilidade Alimentar/complicações , Hipersensibilidade Alimentar/diagnóstico , Glucocorticoides/administração & dosagem , Humanos , Lactente , Recém-Nascido , Fototerapia , Prurido/etiologia , Índice de Gravidade de DoençaAssuntos
Angiofibroma/tratamento farmacológico , Neoplasias Faciais/tratamento farmacológico , Recidiva Local de Neoplasia/prevenção & controle , Sirolimo/administração & dosagem , Neoplasias Cutâneas/tratamento farmacológico , Esclerose Tuberosa/tratamento farmacológico , Administração Cutânea , Adolescente , Fatores Etários , Angiofibroma/diagnóstico , Angiofibroma/etiologia , Criança , Esquema de Medicação , Custos de Medicamentos , Emolientes/administração & dosagem , Neoplasias Faciais/diagnóstico , Neoplasias Faciais/etiologia , Feminino , Humanos , Masculino , Pós , Estudos Retrospectivos , Índice de Gravidade de Doença , Sirolimo/efeitos adversos , Sirolimo/análogos & derivados , Sirolimo/economia , Creme para a Pele/administração & dosagem , Neoplasias Cutâneas/diagnóstico , Neoplasias Cutâneas/etiologia , Comprimidos , Resultado do Tratamento , Esclerose Tuberosa/complicações , Esclerose Tuberosa/diagnósticoRESUMO
Lasers in pediatric dermatology were developed as a result of the treatment of port-wine stains. Infantile hemangiomas may benefit, in some cases, from laser treatment as well as venous and lymphatic malformations. For certain pigmented lesions, as well as some hamartomas, laser treatments are a credible alternative to surgical resection. Bum scars are improved by lasers which stimulate collagen remodeling. Furthermore, hair removal of congenital and acquired hypertrichosis can relieve psychosocial discomfort and improve quality of life. The management of pain and fear of children undergoing laser treatment, using either topical or general anesthesia, remains of central importance.
Assuntos
Terapia a Laser/métodos , Dermatopatias/cirurgia , Fatores Etários , Analgesia/métodos , Criança , Humanos , Terapia a Laser/efeitos adversos , Terapia a Laser/estatística & dados numéricosRESUMO
Genetic tumor syndromes reflect an inherited predisposition to develop benign and malignant tumors. Increased frequency of neoplasms within the family or occurring at an early age are clinical clues for a possible underlying genetic susceptibility. Awareness of their associated cutaneous manifestations can facilitate early detection of risk for tumors. The goal of this article is to review clinical and molecular features of some genetic tumor syndrome which present with skin involvement at birth or during childhood.
Assuntos
Síndromes Neoplásicas Hereditárias/complicações , Dermatopatias/etiologia , Humanos , Síndromes Neoplásicas Hereditárias/diagnóstico , Dermatopatias/patologia , Dermatopatias/terapiaRESUMO
BACKGROUND: In Alzheimer's disease (AD) the olfactory system, including the olfactory bulb, a limbic paleocortex is severely damaged. The occurrence of early olfactory deficits and the presence of senile plaques and neurofibrillary tangles in olfactory bulb were reported previously by a few authors. The goal of the present study was to analyze the occurrence of AD-type degenerative changes in the peripheral part of the olfactory system and to answer the question whether the frequency and severity of changes in the olfactory bulb and tract are associated with those of the cerebral cortex in AD. MATERIAL AND METHODS: In 110 autopsy cases several cortical areas and the olfactory bulb and tract were analyzed using histo- and immunohistochemical techniques. Based on a semiquantitative analysis of cortical senile plaques, neurofibrillary tangles and curly fibers, the 110 cases were divided into four groups: 19 cases with severe (definite AD), 14 cases with moderate, 58 cases with discrete and 19 control cases without AD-type cortical changes. RESULTS: The number of cases with olfactory involvement was very high, more than 84% in the three groups with cortical AD-type lesions. Degenerative olfactory changes were present in all 19 definite AD cases, and in two of the 19 controls. The statistical analysis showed a significant association between the peripheral olfactory and cortical degenerative changes with respect to their frequency and severity (P < 0.001). Neurofibrillary tangles and neuropil threads appear in the olfactory system as early as in entorhinal cortex. CONCLUSION: The results indicate a close relationship between the olfactory and cortical degenerative changes and indicate that the involvement of the olfactory bulb and tract is one of the earliest events in the degenerative process of the central nervous system in AD.
Assuntos
Doença de Alzheimer/patologia , Degeneração Neural/patologia , Transtornos do Olfato/patologia , Bulbo Olfatório/patologia , Condutos Olfatórios/patologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Córtex Cerebral/patologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Emaranhados Neurofibrilares/patologia , Neurópilo/patologia , Placa Amiloide/patologia , Fixação de TecidosRESUMO
A patient with severe postanoxic dystonia and bilateral necrosis of the basal ganglia, who was confined to a wheelchair, underwent bilateral ventralis oralis anterior deep brain stimulation (Voa-DBS) after 6 weeks of unsuccessful bilateral pallidal DBS (GPi-DBS). After 4 months of high intensity Voa-DBS, cognitively unimpaired, he showed major improvement in dystonia, became ambulant, but committed suicide. Brain examination confirmed the correct location of the electrodes in GPi and Voa on both sides.